Importantly, one clinical study reported an exceptional response to sorafenib with near-complete tumor regression in a lung adenocarcinoma patient carrying an ARAF p.S214C mutation [14], highlighting the potential of ARAF mutations in contributing to sorafenib sensitivity in lung cancer. This evidence concerns the gene ARAF and lung adenocarcinoma.